In an interview with Pharmacy Times®, Melissa Santibañez, PharmD, BCCCP, assistant professor at Nova Southeastern University College of Pharmacy, Fort Lauderdale, Florida; and critical care clinical pharmacist at Memorial Regional Hospital, Hollywood, Florida, discusses the value of a pharmacist on a patient care team.
Bhavesh Shah, RPh, BCOP; Brandon Dyson, PharmD, BCOP, BCPS; Ryan Haumschild, PharmD, MS, MBA; and Tim Peterson, PharmD, BCOP, provide advice and strategies for adopting biosimilars into clinical practice.
Rosemarie Leighton, RPh, director of pharmacy, NYC Health + Hospitals/Jacobi, discussed the coordination of COVID-19 vaccinations at the Jacobi Medical Center in the Bronx.
Building on business skills such as negotiating, managing employees, and providing culturally competent care is essential for modern pharmacists, said Shane Desselle, BSPharm, PhD.
Tivozanib was the first therapy approved by the FDA for adult patients with relapsed or refractory advanced renal cell carcinoma following 2 or more prior systemic therapies.
Suzanne Soliman, PharmD, BCMAS, and Sally Arif, PharmD, BCPS, BCCP, discussed the important role of working mothers in the pharmacy field.
For this Mother’s Day, Caroline Carney, MD, MSc, FAPM, CPHQ, explains the importance of understanding the correlation between mental health and heart health in women aged 65 years and older.
Although pharmacists have largely relied on patients coming into their facility, they should begin going out into the community to build trust in COVID-19 vaccines.
The impact of the COVID-19 pandemic on the rate of biosimilar adoption in clinical practice, updates to NCCN guideline recommendations, and financial implications associated with the utilization of biosimilars.
Caroline Carney, MD, MSc, FAPM, CPHQ, chief medical officer of Magellan Health, a board-certified internist, and a board-certified psychiatrist, discusses the impact of trauma and stress on overall health during the COVID-19 pandemic.
IQVIA researchers saw a sharp uptick in medication usage shortly before the COVID-19 pandemic began, followed by a steep fall in the first few months of the pandemic.
In addition to overall concerns about COVID-19 vaccines patients may have stronger fears about the second vaccine dose since it is often accompanied with more adverse effects.
Because several pharmaceutical companies pulled back from the federal 340B program last fall, many patients with diabetes are now seeing skyrocketing insulin prices, according to Anne Webster, NP, with UnityPoint Health.
Experts Suzanne Soliman, PharmD, BCMAS, and Sally Arif, PharmD, BCPS, BCCP, discussed their experiences and advice for handling vaccine hesitancy in part 1 of a 2-part interview on the topic.
The influence of provider buy-in for getting a biosimilar onto formulary and the role of providers in the incorporation of biosimilars are discussed.
Although many patients are hesitant about the COVID-19 vaccines, Humphreys said pharmacists are perfectly positioned to provide education.
Pharmacy Times spoke with Chris Antypas, owner of Asti’s South Hills Pharmacy in Pittsburgh, PA, about the critical role community pharmacists play in bridging the education gap and ensuring access to the COVID-19 vaccine.
Caroline Carney, MD, MSc, FAPM, CPHQ, chief medical officer of Magellan Health, a board-certified internist, and a board-certified psychiatrist, discusses the correlation between heart health and mental health.
Scott J. Knoer, MS, PharmD, FASHP, EVP and CEO of APhA, discussed the value of the pharmacist on patient care teams and how this value could be supported and enhanced in the future.
Although the CDC and FDA have lifted the pause on Johnson & Johnson’s COVID-19 vaccine, Humphreys said the vaccine now comes with a warning label, and ongoing safety reviews will be paramount to ensure its continued safety.
Kenneth Komorny, PharmD, BCPS, a co-lead on development of National Comprehensive Cancer Network recommendations for biosimilar management, explains some of the positions the NCCN has taken.
Multidisciplinary panel of experts share final thoughts on strategies to normalize naloxone and decrease barriers to its obtainment and utilization.
Charles Argoff, MD, leads a discussion on the use of pain contracts versus pain agreements between clinicians and patients to bring about desired outcomes.
Experts discuss the need for and impact of peer-to-peer discussion initiatives, as well as the impact telemedicine utilization has had on the opioid crisis.
Overcoming barriers for payer coverage of biosimilars as well as considerations for carrying costs are discussed.
Brandon Dyson, PharmD, BCOP, BCPS, shares his approach to switching a patient already on biologic therapy to a biosimilar, and panelists discuss the importance of education regarding the extrapolation of indications for biosimilars.
Historic COVID-19 vaccination efforts have illustrated the value of pharmacists, reinforcing many pharmacy students' desire to be a part of the profession.
Pharmacy Times® interviewed Scott J. Knoer, MS, PharmD, FASHP, the EVP and CEO of APhA, on how the recently introduced Pharmacy and Medically Underserved Area Enhancement Act may impact pharmacy and health care outlooks.
Cynthia Lynch, MD, breast cancer program clinical advisor with Cancer Treatment Centers of America, said oncology pharmacists are vital team members who can help ensure optimal treatment and safety for patients with breast cancer.
For World Immunization Week, Pharmacy Times® interviewed Nurisha Wade, MBA, VP of Global Healthcare Quality & Safety Center of Excellence at US Pharmacopeia (USP), and Farah Towfic, PharmD, MBA, director, CEO of Operations at USP, on USP’s COVID-19 Vaccine Handling Toolkit.
